Events

Alerta De Seguridad para Coronary Stents CYPHER Sirolimus-Eluting

Según Agência Nacional de Vigilância Sanitária (ANVISA), este evento ( alerta de seguridad ) involucró a un dispositivo médico en Brazil que fue producido por Cordis Corp A Johnson 403 Johnson Co.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • ID del evento
    749
  • Fecha
    2003-10-30
  • País del evento
    Brazil
  • Fuente del evento
    ANVISA
  • URL de la fuente del evento
    http://www.anvisa.gov.br/sistec/alerta/consultaralerta.asp
  • Notas / Alertas
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Notas adicionales en la data
    BRAZIL - October 30, 2003 - ANVISA. Although, to date, no events related to said product have been communicated to Brazil, and in order to ensure that the health products are safe and effective, ANVISA, through security measures, through the Unit requested the JOHNSON & JOHNSON PROFESSIONALS LTD - BRAZIL which measures the company will adopt in the domestic market, in light of the events reported in the international market, mainly in the United States. BRASIL - NOVEMBER 05, 2003 - JOHNSON & JOHNSON PRODUCTOS PROFISSIONAIS LTDA - BRASIL, in compliance with ANVISA / UTVIG letter no. 90/2003, dated October 30, 2003, states: "That there was no claim or notification of adverse effect relative to the use of the Cypher Coronary stent "
  • Causa
    Fda has issued an fda notice to inform health professionals of reactions of subacute thrombosis (sat) and hypersensitivity with the use of the cypher cordis coronary stent. on october 20, 2003, the fda received more than 290 reports (260 us and 25 outside the us) involving subacute thromboses (sat) associated with the cypher stent. over 60 reports of sats were associated with patient death and the remaining reports were associated with injuries / injuries in the patient who required medical or surgical intervention. the fda has received more than 50 reports, including some deaths, that cordis considers possible hypersensitivity reactions. the symptoms reported include: pain, hives, respiratory changes, fever, itching, and changes in blood pressure.
  • Acción
    FDA reports that so far they have not identified the cause (s) of the events so they can not make specific recommendations. It further informs that as soon as they obtain more information regarding the mechanisms of these events, they will disclose the information. FDA encourages you to follow the instructions for use. For more information on the Cypher stent, see the Instructions for Use at http://www.fda.gov/cdrh/pdf3/P020026c.pdf or the patient guide at http://www.fda.gov/cdrh/pdf3/ P020026d.pdf. For more information on the drug sirolimus, which is marketed as Rapamune, see Medical Instructions for Use at www.fda.gov/cder/foi/label/2003/021083s006lbl.pdf, or see FDA page: http: // www. fda.gov/cdrh/safety/cypher.html

Device

Coronary Stents CYPHER Sirolimus-Eluting

Manufacturer

Cordis Corp A Johnson 403 Johnson Co
  • Source
    ANVSANVISA